Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007

摘要: In order to examine the efficacy and side effects of monoclonal antibody anti-CD20 (rituximab) on autoimmune blistering skin diseases, we performed a comprehensive survey 71 consecutive patients from initial use up 2007, using PubMed database. A heterogeneous group patients, including 51 with pemphigus vulgaris, one vegetans, nine foliaceus, five paraneoplastic pemphigus, four epidermolysis bullosa acquisita, both bullous pemphigoid graft vs host disease was included in this survey. Overall seems be effective that 69% showed complete response, 25% partial whereas 6% progressive disease. Six deaths occurred association treatment, these characteristically resistant conventional medication high mortality rate. Of note, 11 who received combined rituximab intravenous immune globulin treatments had best outcome: response without any serious effects. Therefore further investigation controlled clinical trial is worthy pursuit.